Your browser doesn't support javascript.
loading
A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.
Fountzilas, Christos; Javle, Milind; Tan, Wei; Ma, Yingyu; Fetterly, Gerald; Iyer, Renuka; Johnson, Candace.
Afiliação
  • Fountzilas C; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Javle M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tan W; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Ma Y; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Fetterly G; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Iyer R; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Johnson C; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Cancer ; 124(19): 3890-3899, 2018 10 01.
Article em En | MEDLINE | ID: mdl-30299542
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Ergocalciferóis / Desoxicitidina / Neoplasias Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Ergocalciferóis / Desoxicitidina / Neoplasias Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2018 Tipo de documento: Article